Released: 2/11/2010
Expires: 2/11/2011
Statement of Need
The purpose of this activity is to enhance competence concerning the treatment of patients with multiple myeloma.

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• Describe optimal frontline treatment options for patients with newly diagnosed multiple myeloma (MM)
• List therapeutic options for patients with relapsed/refractory MM
• Describe current opinion on maintenance therapy for MM
• Summarize key clinical data on the use of novel agents in the treatment of MM as presented at the 2009 American Society of Hematology annual meeting

Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes

Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-10-007-H01-P.

Instructions for Credit
There is no fee for this activity. To receive credit, participants must first take the pretest for this activity. After reading this CME activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p10002.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Company	Reported Financial Relationship
Amanda Glazar, PhD	Global	Nothing to disclose
Jackie Dawson, MSN	Global	Nothing to disclose
Nancy Nesser, PharmD, JD	MLI	Nothing to disclose
Kathryn Gada, MSN	MLI	Nothing to disclose
Judy Silman-Greenspan, RPh, MPharm Sci	MLI	Nothing to disclose
Karen Cooksey	COEXM	Nothing to disclose

Faculty Disclosures
Paul Richardson, MD, is on the advisory boards for Bristol-Myers Squibb, Celgene, Johnson & Johnson, and Millennium and has received research support from Millennium.

William Bensinger, MD, is on the speaker's bureau for Celgene, is a consultant to Millennium, and has received research grants from AstraZeneca, Celgene, Genzyme, Geron, Millennium, and Onyx.

Michele Cavo, MD, has no relationships to disclose.

Jean-Luc Harousseau, MD, is on the advisory boards and speaker's bureau for Celgene and Janssen-Cilag.

Sundar Jagannath, MD, is on the advisory boards for Celgene, Merck, and Millennium.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.